This page is for informational purposes only and does not replace medical advice. Please consult Dr Aditya Sarin or a qualified oncologist to understand what your specific tumour marker results mean. As of 2026, this reflects current clinical guidance.

If you’ve had bloodwork done as part of a cancer diagnosis, you’ve probably seen a result labelled CA 125 or CEA and had no idea what it actually meant. Tumour markers show up on a lot of lab reports, but they’re rarely explained well. Here’s what they are, what the common ones actually track, and where they fit into an actual treatment plan.

What is a tumour marker?

A tumour marker is a substance, usually a protein, found in blood, urine, or tissue that can be elevated when cancer is present. According to the National Cancer Institute, tumour markers are mainly used to help diagnose cancer, guide treatment decisions, and monitor how well a treatment is working, not to screen healthy people for cancer in most cases.

That last part matters. Tumour markers aren’t a stand-alone way to find cancer early. With the exception of PSA for prostate cancer, most markers don’t have the accuracy needed for population screening. They’re better understood as one piece of a larger picture that includes imaging, biopsy, and clinical evaluation.

What are the main types of tumour markers?

There are dozens of tumour markers in clinical use, but a handful come up constantly. Each is associated with certain cancer types, though none is exclusive to just one.

CA 125 is most closely linked to ovarian cancer. It’s elevated in roughly 80 per cent of ovarian cancer cases, but it also rises with completely unrelated things like endometriosis, pregnancy, and menstruation, so a high result alone doesn’t confirm cancer.

CEA, or carcinoembryonic antigen, is used primarily to monitor colorectal cancer, both to track treatment response and to catch recurrence after surgery. It’s not used to diagnose colon cancer in the first place, since plenty of non-cancerous conditions, including smoking, can raise it too.

CA 19-9 is associated mainly with pancreatic cancer and is also used in some gastrointestinal cancers. It helps distinguish the nature of a pancreatic mass and track how treatment is going.

AFP, or alpha-fetoprotein, is the main marker for liver cancer and is also used for certain testicular cancers.

PSA is specific to prostate cancer and is the one marker sensitive enough to be used in actual screening programs, though even PSA has known limitations around false positives.

CA 15-3 and CA 27-29 are used mainly to monitor treatment response in metastatic breast cancer, not for initial diagnosis.

What does a tumour marker blood test actually show

A tumour marker test measures the concentration of that specific substance in your blood at one point in time. On its own, a single number rarely tells the full story. What matters more is the trend.

If CA 125 or CEA is rising steadily over several tests, that’s a stronger signal than one high reading. If a marker drops after surgery or chemotherapy and stays low, that generally means treatment is working. If it starts climbing again after being low, that can be an early sign of recurrence, sometimes months before it would show up on a scan.

This is why oncologists tend to order these tests repeatedly through a treatment course rather than once. The pattern over time carries more information than any single result.

Can a tumour marker diagnose cancer on its own

No. This is probably the most important thing to understand about tumour markers. According to the American Cancer Society, an elevated marker can point toward cancer, but confirming a diagnosis still requires imaging and, in most cases, a biopsy.

Several conditions that have nothing to do with cancer can raise these same markers. CA 125 rises with pelvic inflammatory disease. CEA rises in smokers and with inflammatory bowel disease. A normal marker level also doesn’t rule out cancer entirely, since not every tumour produces measurable amounts of a given marker. Some ovarian cancers, for instance, never raise CA 125 at all.

Tumour marker testing in India

Tumour marker blood tests are widely available across major diagnostic labs in India and are a standard part of oncology workups at hospitals like Sir Ganga Ram Hospital. They’re typically ordered alongside imaging such as CT or PET scans rather than in isolation, which is the approach Dr Aditya Sarin follows when building a diagnostic picture for a patient. For markers tied to specific cancers, CA 125 for ovarian cancer, CEA for colorectal cancer, CA 19-9 for pancreatic cancer, or AFP for liver cancer, testing is usually combined with biomarker and genetic profiling to guide not just diagnosis but the choice between treatments like chemotherapy, targeted therapy, or immunotherapy.

The takeaway

Tumour markers are a useful piece of the puzzle, not the whole picture. They’re best at tracking trends over time and monitoring how well treatment is working, and least reliable when used alone to diagnose or rule out cancer. If you’ve got a tumour marker result you don’t understand, book a consultation to have it explained in the context of your actual case.